← Leaderboards
Evan Alexander Scott
Northwestern University
$9,261,535
Attributed
$12,213,771
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2015–25$2.5M$1.9M$1.3M$625K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,213,771 · 10
By mechanism
R01$7,220,657 · 4
DP2$2,317,500 · 1
R21$1,822,795 · 4
U54$852,819 · 1
Top collaborators
- Mark Johnson4 shared
- Chyung-Ru Wang4 shared
- Bruce S Bochner2 shared
- David James Dowling2 shared
- David M. Engman1 shared
Most similar at Northwestern University
Same institution · by research overlap
- Debiao Li$36,112,049
- Mark Johnson$9,553,883
- Guillermo A Ameer$11,495,097
- Jacqueline Alexis Burke$510,000
- Theodore S Jardetzky$26,743,105
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoIn VitroPharmaceutical PreparationsMouse ModelCellsNanocarrierToxic EffectFormulationEngineeringNanoscaleReproducibilityAntigensPropyleneDrug Delivery SystemsTargeted DeliveryMicellesImmunotherapyTissuesHydrogelsDesignAdjuvantDiagnosticInnovationNanostructures
Grant awards (25)
Nanotherapeutic strategies for the treatment of chronic Chagas Disease$666,319
R01 · FY2025 · HL · contact PI
Biomedical Resource Core$319,045
U54 · FY2025 · DK · contact PI
A Nanocarrier Platform for Targeting Schlemm's Canal Cells$265,100
R01 · FY2025 · EY
A Nanocarrier Platform for Targeting Schlemm's Canal Cells$537,141
R01 · FY2024 · EY
A universal multi-drug encapsulation and delivery system employing supramolecular nanogels that self-assemble via dynamic sulfone bonding$429,643
R01 · FY2024 · EB · contact PI
Biomedical Resource Core$203,091
U54 · FY2024 · DK · contact PI
A Nanocarrier Platform for Targeting Schlemm's Canal Cells$543,673
R01 · FY2023 · EY
A universal multi-drug encapsulation and delivery system employing supramolecular nanogels that self-assemble via dynamic sulfone bonding$438,411
R01 · FY2023 · EB · contact PI
Biomedical Resource Core$330,683
U54 · FY2023 · DK · contact PI
Design and characterization of biomimetic nanobiomaterials to elicit CD1-restricted T cell responses during sub-unit vaccination$761,409
R01 · FY2022 · AI · contact PI
A Nanocarrier Platform for Targeting Schlemm's Canal Cells$557,041
R01 · FY2022 · EY · contact PI
A universal multi-drug encapsulation and delivery system employing supramolecular nanogels that self-assemble via dynamic sulfone bonding$438,411
R01 · FY2022 · EB · contact PI
Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cells$230,719
R21 · FY2022 · AI
Identification of the immunomodulatory mechanisms of nanocarrier-enhanced costimulation blockade in an allogeneic portal vein islet transplantation model$189,849
R21 · FY2022 · AI · contact PI
Design and characterization of biomimetic nanobiomaterials to elicit CD1-restricted T cell responses during sub-unit vaccination$761,409
R01 · FY2021 · AI · contact PI
A universal multi-drug encapsulation and delivery system employing supramolecular nanogels that self-assemble via dynamic sulfone bonding$451,422
R01 · FY2021 · EB · contact PI
Identification of the immunomodulatory mechanisms of nanocarrier-enhanced costimulation blockade in an allogeneic portal vein islet transplantation model$230,333
R21 · FY2021 · AI · contact PI
Exploiting Siglec-6 for targeted anti-allergy drug delivery into human mast cells$186,674
R21 · FY2021 · AI
Design and characterization of biomimetic nanobiomaterials to elicit CD1-restricted T cell responses during sub-unit vaccination$685,339
R01 · FY2020 · AI · contact PI
Development and characterization of a nanocarrier for enhanced delivery of benznidazole during acute and chronic T. cruzi infection$294,591
R21 · FY2020 · AI · contact PI
Leveraging immunostimulatory pathways that enhance BCG vaccination for the rational design of synthetic neonatal vaccine formulations$207,000
R21 · FY2020 · AI · contact PI
Design and characterization of biomimetic nanobiomaterials to elicit CD1-restricted T cell responses during sub-unit vaccination$685,339
R01 · FY2019 · AI · contact PI
Leveraging immunostimulatory pathways that enhance BCG vaccination for the rational design of synthetic neonatal vaccine formulations$261,000
R21 · FY2019 · AI · contact PI
Development and characterization of a nanocarrier for enhanced delivery of benznidazole during acute and chronic T. cruzi infection$222,629
R21 · FY2019 · AI
Development of combination immunotherapies for atherosclerotic inflammation$2,317,500
DP2 · FY2015 · HL · contact PI